Downloads: 0 | Views: 112
Research Paper | Medical Microbiology | India | Volume 11 Issue 12, December 2022
Prevalence of Acinetobacter spp in ICU at Tertiary Care Hospital, VIMSAR, BURLA
Dr. Ranjan Kumar Samal | Dr Sudipta Kumar Ram
Abstract: Prevalence of Acinetobacter spp in ICU at tertiary care hospital, VIMSAR, BURLA. Introduction: Acinetobacter spp infections are the emerging pathogen in intensive care units (ICU) patients. Over the last three decades, Acinetobacter spp has transformed from a pathogen of questionable clinical significance to one of the most virulent, multidrug-resistant, pathogenic bacteria in the ICU. So present day study is carried out in Microbiology department of tertiary care hospital and teaching institute. During the study period all samples are collected from patients in ICU of VIMSAR, BURLA and processed for the identification and antimicrobial susceptibility of isolates in microbiology department of VIMSAR, BURLA Aim & Objectives: Primary objective: To identify the prevalence of Acinetobacter spp in clinical sample of ICU patients at VIMSAR, BURLA. Secondary objective: To identify the antibiotic susceptibility pattern of isolated Acinetobacter spp . To correlate the bacteriological profile of Acinetobacter spp with clinical presentation and demographic profile of patients. Materials and Methods: About all clinically significant, consecutive, non-duplicate isolates from various clinical specimens of ICU were included in this prospective study. The isolates were identified by standard protocols and further tested for antimicrobial resistance by Kirby-Bauer disk diffusion method as per CLSI guidelines. Results: From 25 Acinetobacter isolates, majority were from sputum (24%), endotracheal aspirate (20%), pus (8%), blood (8%) followed by other samples. The present study, Acinetobacter spp. showed high level of resistance to, Cefotaxime (92%), Ciprofloxacin (92%), Cotrimoxazole (88%), Ampicillin + sulbactam(88%), Cefepime (84%), Ceftazidime(84%) Gentamicin (80%), and Amikacin(76%), Piperacillin+Tazobactum (76%), Imipenem (56%).
Keywords: Acinetobacter species, nosocomial infection, antimicrobial resistance, MDR, CSLI, disk diffusion
Edition: Volume 11 Issue 12, December 2022,
Pages: 666 - 669